Ranibizumab for the treatment of degenerative ocular conditions

Magdalini Triantafylla,1 Horace F Massa,2 Doukas Dardabounis,1 Zisis Gatzioufas,2 Vassilios Kozobolis,1 Konstantinos Ioannakis,1 Irfan Perente,1,3 Georgios D Panos1,21Department of Ophthalmology, University General Hospital of Alexandroupolis, School of Medicine, University of Thrace, Alexandroupol...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Triantafylla M, Massa HF, Dardabounis D, Gatzioufas Z, Kozobolis V, Ioannakis K, Perente I, Panos GD
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2014
Materias:	Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/888ee8ee09a3493180f43a1315615dda
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:888ee8ee09a3493180f43a1315615dda
record_format	dspace
spelling	oai:doaj.org-article:888ee8ee09a3493180f43a1315615dda2021-12-02T07:41:33ZRanibizumab for the treatment of degenerative ocular conditions1177-5483https://doaj.org/article/888ee8ee09a3493180f43a1315615dda2014-06-01T00:00:00Zhttp://www.dovepress.com/ranibizumab-for-the-treatment-of-degenerative-ocular-conditions-a17324https://doaj.org/toc/1177-5483 Magdalini Triantafylla,1 Horace F Massa,2 Doukas Dardabounis,1 Zisis Gatzioufas,2 Vassilios Kozobolis,1 Konstantinos Ioannakis,1 Irfan Perente,1,3 Georgios D Panos1,21Department of Ophthalmology, University General Hospital of Alexandroupolis, School of Medicine, University of Thrace, Alexandroupolis, Greece; 2Department of Ophthalmology, Geneva University Hospitals, Faculty of Medicine, University of Geneva, Switzerland; 3Beyoglou Eye Research and Teaching Hospital, Istanbul University, Istanbul, TurkeyAbstract: Degenerative ocular conditions, such as age-related macular degeneration, diabetic retinopathy, retinal vein occlusions, and myopic degeneration, have become a major public health problem and a leading cause of blindness in developed countries. Anti-vascular endothelial growth factor (VEGF) drugs seem to be an effective and safe treatment for these conditions. Ranibizumab, a humanized monoclonal antibody antigen-binding fragment, which inhibits all biologically active isoforms of VEGF-A, is still the gold standard treatment for the majority of these pathological entities. In this review, we present the results of the most important clinical trials concerning the efficacy and safety of ranibizumab for the treatment of degenerative ocular conditions.Keywords: age-related macular degeneration, diabetic macular edema, retinal vein occlusion, anti-VEGF, safety, efficacy, quality of lifeTriantafylla MMassa HFDardabounis DGatzioufas ZKozobolis VIoannakis KPerente IPanos GDDove Medical PressarticleOphthalmologyRE1-994ENClinical Ophthalmology, Vol 2014, Iss default, Pp 1187-1198 (2014)
institution	DOAJ
collection	DOAJ
language	EN
topic	Ophthalmology RE1-994
spellingShingle	Ophthalmology RE1-994 Triantafylla M Massa HF Dardabounis D Gatzioufas Z Kozobolis V Ioannakis K Perente I Panos GD Ranibizumab for the treatment of degenerative ocular conditions
description	Magdalini Triantafylla,1 Horace F Massa,2 Doukas Dardabounis,1 Zisis Gatzioufas,2 Vassilios Kozobolis,1 Konstantinos Ioannakis,1 Irfan Perente,1,3 Georgios D Panos1,21Department of Ophthalmology, University General Hospital of Alexandroupolis, School of Medicine, University of Thrace, Alexandroupolis, Greece; 2Department of Ophthalmology, Geneva University Hospitals, Faculty of Medicine, University of Geneva, Switzerland; 3Beyoglou Eye Research and Teaching Hospital, Istanbul University, Istanbul, TurkeyAbstract: Degenerative ocular conditions, such as age-related macular degeneration, diabetic retinopathy, retinal vein occlusions, and myopic degeneration, have become a major public health problem and a leading cause of blindness in developed countries. Anti-vascular endothelial growth factor (VEGF) drugs seem to be an effective and safe treatment for these conditions. Ranibizumab, a humanized monoclonal antibody antigen-binding fragment, which inhibits all biologically active isoforms of VEGF-A, is still the gold standard treatment for the majority of these pathological entities. In this review, we present the results of the most important clinical trials concerning the efficacy and safety of ranibizumab for the treatment of degenerative ocular conditions.Keywords: age-related macular degeneration, diabetic macular edema, retinal vein occlusion, anti-VEGF, safety, efficacy, quality of life
format	article
author	Triantafylla M Massa HF Dardabounis D Gatzioufas Z Kozobolis V Ioannakis K Perente I Panos GD
author_facet	Triantafylla M Massa HF Dardabounis D Gatzioufas Z Kozobolis V Ioannakis K Perente I Panos GD
author_sort	Triantafylla M
title	Ranibizumab for the treatment of degenerative ocular conditions
title_short	Ranibizumab for the treatment of degenerative ocular conditions
title_full	Ranibizumab for the treatment of degenerative ocular conditions
title_fullStr	Ranibizumab for the treatment of degenerative ocular conditions
title_full_unstemmed	Ranibizumab for the treatment of degenerative ocular conditions
title_sort	ranibizumab for the treatment of degenerative ocular conditions
publisher	Dove Medical Press
publishDate	2014
url	https://doaj.org/article/888ee8ee09a3493180f43a1315615dda
work_keys_str_mv	AT triantafyllam ranibizumabforthetreatmentofdegenerativeocularconditions AT massahf ranibizumabforthetreatmentofdegenerativeocularconditions AT dardabounisd ranibizumabforthetreatmentofdegenerativeocularconditions AT gatzioufasz ranibizumabforthetreatmentofdegenerativeocularconditions AT kozobolisv ranibizumabforthetreatmentofdegenerativeocularconditions AT ioannakisk ranibizumabforthetreatmentofdegenerativeocularconditions AT perentei ranibizumabforthetreatmentofdegenerativeocularconditions AT panosgd ranibizumabforthetreatmentofdegenerativeocularconditions
_version_	1718399234220228608

Ranibizumab for the treatment of degenerative ocular conditions

Ejemplares similares